secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001737287-22-000065
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene expects FDA clearance for first allogeneic CAR T pivotal trial; Q2 net loss $74.8M
--------------------------------------------------------------------------------

- FDA clearance expected in coming weeks for Phase 2 pivotal trial of ALLO-501A in LBCL; would be first allogeneic CAR T pivotal trial.
- Ended Q2 2022 with $686M cash, cash equivalents and investments; net loss $74.8M ($0.52 per share).
- Full year GAAP OpEx guided to low end of $360M-$390M; cash burn ~$250M for 2022.
- CF1 manufacturing facility operational; projected capacity ~20,000 doses/year; earned LEED Gold designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000065/0001737287-22-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000065/allo-20220809.htm
  HTML page:      https://secwatch.observer/filing/0001737287-22-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer